"Now, we have cursorily looked at the active ingredients, and have some issues on the scientific underpinnings. It basically relates to the theory of hormesis, which is a fancy way of saying a small amount of a thing that is bad for you is good for you. It is what homeopathic medicine relies upon. There is some truth to it, in some therapeutic paradigms, but we see it misapplied all the time. So we will be peppering their scientific advisor with questions once this gets fully underway."
Okay, so let's address hormesis. Hopefully these links will make it easier for Dr. John, Dr. George and the BFT readers to see more than just a cursory look at our science.
Professor Ko has offered up 3 papers he has published on this topic.
The first:
Frontiers in Research:
Herbal Bioactive Molecules: The Hidden Jewels for Drug Development
Mitochondrial decay in ageing: ‘Qi-invigorating’ schisandrin B as a hormetic agent for mitigating age-related diseases
SUMMARY
1. The mitochondrial free radical theory of ageing (MFRTA) proposes a primary role for mitochondrial reactive oxygen species (ROS) in the ageing process. The reductive hot spot hypothesis of mammalian ageing serves as a supplement to the MFRTA by explaining how the relatively few cells that have lost oxidative phosphorylation capacity due to mitochondrial DNA mutations can be toxic to the rest of the body and result in the development of age-related diseases.
2. Schisandrin B (SchB), which can induce both a glutathione anti-oxidant and a heat shock response via redox-sensitive signalling pathways, is a hormetic agent potentially useful for increasing the resistance of tissues to oxidative damage. The enhanced cellular ⁄mitochondrial anti-oxidant status and heat shock
response afforded by SchB can preserve the structural and functional integrity of mitochondria, suggesting a potential role for SchB in ameliorating age-related diseases.
3. Future studies will focus on investigating whether SchB can produce the hormetic response in humans.
Click here for a link to the study
The second
Schisandrin B as a Hormetic Agent for Preventing Age-Related Neurodegenerative Diseases
SUMMARY
Oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of neurodegenerative diseases, with the latter preceding the appearance of clinical symptoms. The energy failure resulting from mitochondrial dysfunction further impedes brain function, which demands large amounts of energy. Schisandrin B (Sch B), an active ingredient isolated from Fructus Schisandrae, has been shown to afford generalized tissue protection against oxidative damage in various organs, including the brain, of experimental animals. Recent experimental findings have further demonstrated that Sch B can protect neuronal cells against oxidative challenge, presumably by functioning as a hormetic agent to sustain cellular redox homeostasis and mitoenergetic capacity in neuronal cells. The combined actions of Sch B offer a promising prospect for preventing or possibly delaying the onset of neurodegenerative diseases, as well as enhancing brain health.
Click here for a link to the study
The third
Schisandrin B enhances the glutathione redox cycling and protects against oxidant injury in different types of cultured cells
SUMMARY
Tert-butylhydroperoxide (tBHP) challenge caused an initial depletion of cellular reduced glutathione (GSH), which was followed by a gradual restoration of cellular GSH in AML12, H9c2, and differentiated PC12 cells. The time-dependent changes in cellular GSH induced by tBHP were monitored as a measure of GSH recovery capacity (GRC), of which glutathione reductase (GR)-mediated glutathione redox cycling and c-glutamate cysteine ligase (GCL)-mediated GSH synthesis were found to play an essential role. While glutathione redox cycling sustained the GSH level during the initial tBHP-induced depletion, GSH synthesis restores the GSH level thereafter. The effects of (- )schisandrin B [(- )Sch B] and its analogs (Sch A and Sch C) on GRC were also examined in the cells. (- )Sch B and Sch C, but not Sch A, ameliorated the extent of tBHP-induced GSH depletion, indicative of enhanced glutathione redox cycling. However, the degree of restoration of GSH post-tBHP challenge was not affected or even decreased. Pretreatment with
(- )Sch B and Sch C, but not Sch A, protected against oxidant injury in the cells. The (- )Sch B afforded cytoprotection was abolished by N,N0-bis(chloroethyl)-N-nitrosourea pretreatment suggesting the enhancement of glutathione redox cycling is crucially involved in the cytoprotection afforded by (- )Sch B against oxidative stress-induced cell injury.
Click here for a link to the study
And here is just a quick response to this post.
http://barefacedtruth.com/2014/06/25/from-theory-to-glissandra/#comment-130371
Not to be picky, but I am compelled to gently point out that the Glissandra web site on its home page makes this claim:
“Glissandra™ is the first bioceutical skincare regimen proven to effectively reduce the visible signs of skin aging.”
Oh, really? It’s one thing to brag and say you are the best, but telling us that all the other products in the biologic category are ineffective and do nada for skin aging? Now you either need to prove that claim (no others are effective except yours) or confess to indulgence in marketing hype.
I don't see where we say that other products in the biologic category are ineffective and do nada for skin aging. If I read this correctly, it simply says Glissandra™ is the first. Come on Dr. John, no need to run when nobody is chasing you. We coined the term bioceutical in 2008 by combining biology and nutraceutical as a marketing term. I guess others liked the term and are using it now.